HopeStage
Back to all studies
CompletedNCT02600494

Lumateperone Alone for Bipolar Depression

About this title

Clinical Trial Evaluating ITI-007 (Lumateperone) as a Monotherapy for the Treatment of Bipolar Depression

Read the official source — NCT02600494

Researchers compared ITI-007 (Lumateperone) and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Medication studyAges 18–75United States
The study in practice

Understand this study

What did researchers investigate?

Researchers compared ITI-007 (Lumateperone) and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Listed locations
Little Rock and 54 more locationsSee all locations and recruitment
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: December 15, 2015
Recruitment status
Completed
Enrollment listed in the registry
554
Sponsor
Intra-Cellular Therapies, Inc.
Sponsor type
Other organization
Study type
Drug
Intervention type
Drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
United States
Age range
From 18 Years to 75 Years
Official registry ID
NCT02600494
Official title
Show the full official title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Assess the Efficacy and Safety of ITI-007 Monotherapy in the Treatment of Patients With Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder (Bipolar Depression)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Little Rock · Rogers · Cerritos

52 more locations
  • Culver City
  • Garden Grove
  • Lemon Grove
  • National City
  • Oakland
  • Oceanside
  • Orange
  • Pico Rivera
  • Riverside
  • San Diego
  • San Marcos
  • Santa Rosa
  • Colorado Springs
  • Bradenton
  • Fort Myers
  • Jacksonville
  • Lauderhill
  • Miami
  • North Miami
  • Orlando
  • Atlanta
  • Chicago
  • Hoffman Estates
  • Lake Charles
  • Baltimore
  • Boston
  • O'Fallon
  • St Louis
  • Las Vegas
  • Berlin
  • Cherry Hill
  • Marlton
  • Toms River
  • Brooklyn
  • Cedarhurst
  • New York
  • Rochester
  • Staten Island
  • Cincinnati
  • Cleveland
  • Dayton
  • Garfield Heights
  • Oklahoma City
  • Allentown
  • Norristown
  • Philadelphia
  • Memphis
  • Austin
  • Dallas
  • Houston
  • Petersburg
  • Everett

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

What did researchers investigate?

Researchers compared ITI-007 (Lumateperone) and placebo to find out how the approaches affected depression symptoms in people with bipolarity type II during a depressive episode.

Who is behind this study?

The study sponsor is Intra-Cellular Therapies, Inc.

Did this study involve medication?

Yes. The study involved medication, including ITI-007 (Lumateperone) and Placebo.

Who was this study for?

This study was for people with bipolarity. Listed age limits: 18 years to 75 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies